Fig. 6

Evaluation of the biosafety of HCR NPs in vivo. A The body weight of mice in each group was measured at the indicated time points. B-E Blood biochemical markers: ALT (B); AST (C); UREAL (D); CREJ (E). Each group was tested five times in parallel. F Representative heart, liver, spleen, lung, and kidney H&E staining at the end of the treatment period of mice bearing DLD-1 xenografts treated with vehicle, CLT-IR820 or HCR NPs intravenously through the tail vein. Scale bar: 40 μm